CTERA Extends Microsoft 365 Copilot to the Enterprise File Estate, with Governed, Classified and Searchable Data to Improve AI Quality and Outcomes

Enterprise organizations can securely connect their enriched CTERA data to Microsoft Copilot across hybrid environments without moving files or compromising governance

Enterprise organizations can securely connect their enriched CTERA data to Microsoft Copilot across hybrid environments without moving files or compromising governance

Nocera Advances AI Infrastructure Strategy with Agreement to Acquire QMAX Technology, a Taiwan-Based Authorized Distributor of Micron / Crucial Memory and Storage Products

Acquisition Secures Authorized Memory Sales Qualifications and Distribution Channels, Connecting Nocera’s Planned AI Data Center Build-Out with the Memory and Storage Supply Chain at the Core of the Global AI Economy

Acquisition Secures Authorized Memory Sales Qualifications and Distribution Channels, Connecting Nocera’s Planned AI Data Center Build-Out with the Memory and Storage Supply Chain at the Core of the Global AI Economy

Syntec Optics (NASDAQ: OPTX) Secures New Space Order, Expanding Footprint from Orbital Highway to Critical Orbital Safety

ROCHESTER, NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (Nasdaq: OPTX), a leading provider of deep tech for the defense, space, and other vibrant end-markets, today announced a major new production order to launch an additional space optics product line. This expansion addresses the urgent, rapidly growing market demand for advanced collision avoidance optics in low Earth orbit.

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Processa) (Nasdaq: PCSA) today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis.

Quantum Cyber Applauds President Trump’s Drone Dominance Program and Supply Chain Framework, Reaffirms Commitment to On-Shore U.S. Manufacturing of Autonomous Systems

Company Views the Department of War’s Drone Dominance Program Supply Chain Framework as Direct Validation of Its Domestic Manufacturing Strategy Led by Peter O’Rourke and David Lazar; Bridgeport, Connecticut Facility Positioned to Support Non-Covered-Country Sourcing Requirements

Company Views the Department of War's Drone Dominance Program Supply Chain Framework as Direct Validation of Its Domestic Manufacturing Strategy Led by Peter O'Rourke and David Lazar; Bridgeport, Connecticut Facility Positioned to Support Non-Covered-Country Sourcing Requirements